Liminatus Pharma, Inc. Class A Common Stock

LIMN

NASDAQHealthcareBiotechnology

Open in GoAI

Latest quote

$3.62

−$0.09 · -2.43%

Company profile

Liminatus Pharma, Inc. is an immuno-oncology firm, currently in its clinical development phase, dedicated to pioneering new treatments for cancer. The company's headquarters are located in La Palma, California.

Liminatus Pharma, Inc. Class A Common Stock

LIMN

NASDAQHealthcareBiotechnology

Open in GoAI

Previous close

$3.62

−$0.09 · -2.43%

Sep 8, 4:00 PM ET

Latest quote

$3.62

−$0.09 · -2.43%

After-hours

$3.62

$0.00 · 0.00%

Sep 8, 7:30 PM ET

Regular session · ET · Market data may be delayed.

GoAI snapshot

Jul 10, 2026

39/ 100

GoAI Score

Sell

Valuation

Fair Value

Sentiment

Mixed

Risk

High Risk

Momentum

Strong Down

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

Company profile

Company website

Industry: Biotechnology
Sector: Healthcare
Headquarters: US
CEO: Chris Kim
Listed since: May 1, 2025
Employees: 1

Market position

Day range

Current $3.62

$3.52$3.725

52-week range

Current $3.62

$3.42$141.5

Open: $3.72
Previous close: $3.71
Volume: 26.13K; 0.05× average
Average volume: 578.8K; Average daily volume
Market cap: 4.86M USD
Beta: 0.71; Market reference 1
50-day average: $5.5047; -34.24% below average
200-day average: $18.4647; -80.40% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value: 15.59M USD
P/E (TTM): -0.15×
P/B (TTM): 5.72×
P/S (TTM): 0×
EV / EBITDA: -1.56×
Earnings yield: -70.44%
Free cash flow yield: -68.85%
Dividend yield: 0.00%

Profitability & efficiency

Gross margin: 0.00%
Operating margin: 0.00%
Net margin: 0.00%
Return on equity: 103.99%
Return on assets: -1990.37%
Return on invested capital: 35.57%

Financial health

Debt / equity: 4.8×
Current ratio: 0.05×
Altman Z-score: -28
Piotroski F-score: 2 of 9

Financial statements

Income trends

Operating income

−2.97M USD-2.12%

Net income

−10.21M USD-251.43%

Financial statements: Income statement
Metric (USD)	FY2025	FY2024	FY2023	FY2022	FY2021
Research and development	—	2.69M USD	3.76M USD	1.85M USD	3.8M USD
Selling, general, and administrative	2.97M USD	645K USD	1.06M USD	856K USD	197K USD
Operating expenses	2.97M USD	2.91M USD	2.59M USD	2.71M USD	2.53M USD
Interest income	76.59K USD	137.72K USD	10K USD	—	16.84K USD
Interest expense	215.9K USD	138.1K USD	175K USD	219K USD	—
Depreciation and amortization	1.83K USD	—	—	1K USD	—
Operating income	−2.97M USD	−2.91M USD	−2.59M USD	−2.71M USD	−2.53M USD
Net income	−10.21M USD	−2.9M USD	−1.23M USD	−2.93M USD	4.37M USD

Company facts updated Sep 9, 2026.

Earnings

Latest fiscal-year EPS: -21.5; FY2025
Latest fiscal-year revenue: 0 USD; FY2025

Annual EPS trend

Reported history and fiscal-year consensus

ReportedConsensus forecast

Annual revenue trend

Reported history and fiscal-year consensus

ReportedConsensus forecast

LIMN peers

AMGN

Amgen Inc.

$393.17

-10.08%

GILD

Gilead Sciences, Inc.

$146.64

-2.88%

VRTX

Vertex Pharmaceuticals Incorporated

$528.9

-3.15%

ISRG

Intuitive Surgical, Inc.

$350.16

-4.51%

SNY

Sanofi

$43.155

-2.45%

REGN

Regeneron Pharmaceuticals, Inc.

$810.31

-2.10%

ETFs holding LIMN

Funds reporting this stock among their holdings, ordered by reported position size.

ETFMarket valueWeightAUMExpense ratioPrice / 1D

Vanguard Extended Market ETFVXF5.2K0.00%93.7B USD0.05%$241.35-0.54%

Vanguard Extended Market ETFVXF

Market value: 5.2K
Weight: 0.00%
AUM: 93.7B USD
Expense ratio: 0.05%
Price / 1D: $241.35-0.54%

Continue in GoAI

Research LIMN

AI-generated and delayed market data for informational and educational purposes only. Not investment advice.

Regular session · ET · Market data may be delayed.

Company profile

Company website

Industry: Biotechnology
Sector: Healthcare
Headquarters: US
CEO: Chris Kim
Listed since: May 1, 2025
Employees: 1

Market position

Day range

Current $3.62

$3.52$3.725

52-week range

Current $3.62

$3.42$141.5

Open: $3.72
Previous close: $3.71
Volume: 26.13K; 0.05× average
Average volume: 578.8K; Average daily volume
Market cap: 4.86M USD
Beta: 0.71; Market reference 1
50-day average: $5.5047; -34.24% below average
200-day average: $18.4647; -80.40% below average

Company profile

Regular session · ET · Market data may be delayed.

GoAI snapshot

Jul 10, 2026

39/ 100

GoAI Score

Sell

Valuation

Fair Value

Sentiment

Mixed

Risk

High Risk

Momentum

Strong Down

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

Company profile

Company website

Industry: Biotechnology
Sector: Healthcare
Headquarters: US
CEO: Chris Kim
Listed since: May 1, 2025
Employees: 1

Market position

Day range

Current $3.62

$3.52$3.725

52-week range

Current $3.62

$3.42$141.5

Open: $3.72
Previous close: $3.71
Volume: 26.13K; 0.05× average
Average volume: 578.8K; Average daily volume
Market cap: 4.86M USD
Beta: 0.71; Market reference 1
50-day average: $5.5047; -34.24% below average
200-day average: $18.4647; -80.40% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value: 15.59M USD
P/E (TTM): -0.15×
P/B (TTM): 5.72×
P/S (TTM): 0×
EV / EBITDA: -1.56×
Earnings yield: -70.44%
Free cash flow yield: -68.85%
Dividend yield: 0.00%

Profitability & efficiency

Gross margin: 0.00%
Operating margin: 0.00%
Net margin: 0.00%
Return on equity: 103.99%
Return on assets: -1990.37%
Return on invested capital: 35.57%

Financial health

Debt / equity: 4.8×
Current ratio: 0.05×
Altman Z-score: -28
Piotroski F-score: 2 of 9

Financial statements

Income trends

Operating income

−2.97M USD-2.12%

Net income

−10.21M USD-251.43%

Financial statements: Income statement
Metric (USD)	FY2025	FY2024	FY2023	FY2022	FY2021
Research and development	—	2.69M USD	3.76M USD	1.85M USD	3.8M USD
Selling, general, and administrative	2.97M USD	645K USD	1.06M USD	856K USD	197K USD
Operating expenses	2.97M USD	2.91M USD	2.59M USD	2.71M USD	2.53M USD
Interest income	76.59K USD	137.72K USD	10K USD	—	16.84K USD
Interest expense	215.9K USD	138.1K USD	175K USD	219K USD	—
Depreciation and amortization	1.83K USD	—	—	1K USD	—
Operating income	−2.97M USD	−2.91M USD	−2.59M USD	−2.71M USD	−2.53M USD
Net income	−10.21M USD	−2.9M USD	−1.23M USD	−2.93M USD	4.37M USD

Company facts updated Sep 9, 2026.

Earnings

Latest fiscal-year EPS: -21.5; FY2025
Latest fiscal-year revenue: 0 USD; FY2025

Annual EPS trend

Reported history and fiscal-year consensus

ReportedConsensus forecast

Annual revenue trend

Reported history and fiscal-year consensus

ReportedConsensus forecast

LIMN peers

AMGN

Amgen Inc.

$393.17

-10.08%

GILD

Gilead Sciences, Inc.

$146.64

-2.88%

VRTX

Vertex Pharmaceuticals Incorporated

$528.9

-3.15%

ISRG

Intuitive Surgical, Inc.

$350.16

-4.51%

SNY

Sanofi

$43.155

-2.45%

REGN

Regeneron Pharmaceuticals, Inc.

$810.31

-2.10%

ETFs holding LIMN

Funds reporting this stock among their holdings, ordered by reported position size.

ETFMarket valueWeightAUMExpense ratioPrice / 1D

Vanguard Extended Market ETFVXF5.2K0.00%93.7B USD0.05%$241.35-0.54%

Vanguard Extended Market ETFVXF

Market value: 5.2K
Weight: 0.00%
AUM: 93.7B USD
Expense ratio: 0.05%
Price / 1D: $241.35-0.54%

Continue in GoAI

Research LIMN

AI-generated and delayed market data for informational and educational purposes only. Not investment advice.

Liminatus Pharma, Inc. Class A Common Stock

LIMN company overview

Company profile

Liminatus Pharma, Inc. Class A Common Stock

LIMN company overview

GoAI snapshot

Company profile

Market position

Financials

Financial snapshot

Valuation & yield

Profitability & efficiency

Financial health

Financial statements

Income trends

Earnings

Annual EPS trend

Annual revenue trend

LIMN peers

ETFs holding LIMN

Continue in GoAI

LIMN company overview

Company profile

Market position

LIMN company overview

Company profile

LIMN company overview

Company profile

Market position

LIMN company overview

GoAI snapshot

Company profile

Market position

Financials

Financial snapshot

Valuation & yield

Profitability & efficiency

Financial health

Financial statements

Income trends

Earnings

Annual EPS trend

Annual revenue trend

LIMN peers

ETFs holding LIMN

Continue in GoAI